Resources
12 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 6/2/2021 (updated 4/10/2024)
This webinar provided a review of basic principles of integrated behavioral health and an update on recent outcomes and implementation research.
Posted 8/4/2021 (updated 4/2/2024)
Posted 10/7/2020 (updated 3/29/2024)
This toolkit contains clinical materials targeting treatment of substance use disorder in the acute care setting.
Posted 9/1/2020 (updated 3/29/2024)
To raise awareness of increasing overdose events and deaths related to cocaine and other stimulant use, and to provide guidance to health care providers on clinically managing and preventing harm from cocaine and stimulant use disorders.
Posted 1/24/2020 (updated 3/28/2024)
Get Naloxone Now is an online resource to train people to respond effectively to an opioid overdose emergency.
Posted 5/13/2020 (updated 3/28/2024)
This was the second session in the telehealth series. There were various speakers and panelists from agencies including JBS International, Global Partnership for Telehealth, H.O.P.E. Telehealth Consortium, HRSA’s Office for the Advancement of Telehealth, and the Telehealth Resource Centers.
Posted 8/18/2020 (updated 3/28/2024)
This guide was created for harm reduction medical staff and volunteers as a resource about the types of wounds common with injection drug use and also to increase knowledge about treatment modalities for this population. Skin and soft-tissue infections are the most common cause of hospitalization among people who inject drugs.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Treasury Room on Wednesday, March 4, 2020, at 4:15 PM
Posted 7/27/2020 (updated 3/28/2024)
The American Medical Association’s Opioid Task Force report shows a dramatic increase in fatalities involving illicit opioids, stimulants (e.g. methamphetamine), heroin and cocaine and a similarly dramatic drop in the use of prescription opioids.
Posted 1/17/2023 (updated 3/27/2024)
The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.